Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

开始日期2025-10-17

申办/合作机构

City of Hope National Medical Center

[+1]

NCT06904378

/ Not yet recruiting临床1/2期IIT

Phase I/II Clinical Trial of Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells

The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of Ontegimod with gemcitabine and nab-paclitaxel in unresectable pancreatic ductal adenocarcinoma prior to future studies incorporating anti-PD1 checkpoint immunotherapy.

开始日期2025-07-31

申办/合作机构

Washington University School of Medicine

[+1]

NCT06897046

/ Not yet recruiting临床2期IIT

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC

开始日期2025-07-10

申办/合作机构

中国医学科学院肿瘤医院

100 项与白蛋白结合型紫杉醇相关的临床结果

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的转化医学

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的专利（医药）

登录后查看更多信息

42,640

项与白蛋白结合型紫杉醇相关的文献（医药）

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies

Article

作者: Bartuzi, Damian ; Stepulak, Andrzej ; Okon, Estera ; Kalafut, Joanna ; Wawruszak, Anna ; Czerwonka, Arkadiusz ; Luszczki, Jarogniew

Sirtuins (SIRTs) are NAD+-dependent histone deacetylases, which play a key role in cancer progression; however, their prognostic values in breast cancer (BC) remain a subject of debate and controversy. Accumulative evidence suggests that each sirtuin possesses individual character, implicating its role in the regulation of multifaceted biological functions leading to BC initiation, progression and metastasis. Selisistat (EX527) is a potent, cell permeable, highly selective SIRT1 inhibitor. In the study, the tumour-suppressive effects of the SIRT1 inhibitor EX527 (selisistat) alone and in combination with paclitaxel (PAX) in different breast cancer cell lines and zebrafish xenograft models were investigated. The type of pharmacological drug-drug interaction between EX527 and PAX was determined using the isobolographic method. EX527 and PAX used individually inhibited proliferation, induced apoptosis and caused cell cycle arrest in G1 and subG1/G2 phases. Interestingly, the combination of these compounds used in the 1:1 dose-ratio augmented all these effects (IC_50add 29.52 ± 3.29 - 38.45 ± 5.26). The co-treatment of EX527 with PAX generated desirable additive drug-drug interaction. The simultaneous application of EX527 and PAX induced a stronger inhibition of tumour growth compared to individual treatments in zebrafish xenografts. In silico analysis revealed a protein-protein interaction pathway (SIRT1-AKT-S1PR1-GNAI1/GNAO1-Tubulin) connecting molecular targets of both ligands. To summarise, the combination of EX527 and PAX more effectively impairs breast cancer cell growth compared to individual treatments. However, further investigations are required to clarify the specific targets and molecular mechanisms underlying the activity of EX527:PAX in other preclinical models.

2025-08-01·Current Drug Safety

Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review

Article

作者: Xu, Xiangqian ; Xue, Honghao ; Lu, Chenghua ; Guo, Xiaoyan ; Zhou, Yanshi ; Zhang, Yemin ; Zhang, Jun ; Wu, Qingyuan ; Xie, Shiyun

Background::

Non-small Cell Lung Cancer (NSCLC) makes up about 85% of lung cancer cases, mainly adenocarcinoma and squamous cell carcinoma. Recently, PD-1 inhibitors have become crucial in NSCLC treatment, significantly enhancing survival for some. However, side effects, like skin reactions and hematotoxicity, limit their use, with drug-induced TEN and immunotherapy-induced agranulocytosis as severe adverse effects.

Case Presentation::

Herein, we have reported the case of a 75-year-old male diagnosed with metastatic Lung Squamous cell Carcinoma (LUSC) in the left lung. He received first-line treatment with one cycle of tislelizumab in combination with nab-paclitaxel and carboplatin, after which he developed Toxic Epidermal Necrolysis (TEN) and granulocytopenia. To address these two serious immune-related Adverse Events (irAEs), the patient was administered methylprednisolone in combination with gamma globulin for TEN and dexamethasone in combination with G-CSF for agranulocytosis. Antibiotics were also administered according to the patient’s medication regimen. After treatment, the patient recovered and was discharged from the hospital. It was also noted that the lung tumor condition improved.

Conclusion::

Effective management of severe immune-related side effects from tislelizumab, including TEN and agranulocytosis, can be partly achieved through steroids, gamma globulin, GCSF, and antibiotics. This strategy not only alleviates these adverse effects, but also potentially improves tumor conditions, highlighting the crucial role of vigilant monitoring and management in immunotherapy.

2025-07-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effect of Astragalus polysaccharide combined with cisplatin on exhaled volatile organic compounds as biomarkers for lung cancer and its anticancer mechanism

Article

作者: Shi, Wenmin ; Feng, Weisheng ; Zhang, Zhijuan ; Zhang, Huanqing ; Tang, Hanxiao

Cisplatin (DDP) is widely used to fight lung cancer, but there is a risk of immune damage. Astragalus polysaccharides (APS) is the main active component of Astragalus membranaceus Bunge. It has demonstrated anticancer properties across a range of cancer types as well as to be effective against cisplatin induced immune damage. However, its therapeutic mechanism has not been fully explored. This study aimed to explore the antitumor mechanisms of APS and elucidate the relationship between APS and volatile organic compounds (VOCs) in exhaled breath of Lewis lung cancer (LLC) mice. Gas chromatography-mass spectrometry (GC-MS) was utilized to analyze the exhaled VOCs in LLC mice. A specific group of VOCs was identified as potential biomarkers for monitoring tumor progression. Furthermore, the effects of combined treatment with APS and DDP on the concentration of exhaled VOCs in LLC mice was evaluated. Stoichiometric analysis revealed that the levels of 12 VOCs exhibited substantial recovery following APS treatment. And a high concentration of APS (400 mg/kg), when combined with DDP, exhibited enhanced antitumor efficacy. The metabolic pathways involved in the action of APS include 12 pathways. Our methodology elucidated both the effects and mechanisms of APS on lung cancer, as well as the pharmacological enhancement of cisplatin by APS. These findings facilitate real-time monitoring of lung cancer treatments and contribute to the future development of anticancer therapies.

1,285

项与白蛋白结合型紫杉醇相关的新闻（医药）

2025-04-24

·医药魔方

2025Q1财报出炉：默沙东、罗氏、赛诺菲、BMS……

制药巨头陆续公布2025Q1财报。面对专利到期、市场竞争和政策环境压力，MNC公司继续在创新产品和全球市场扩张上寻找增长机会。本文汇总默沙东、罗氏、赛诺菲、百时美施贵宝的第一季度表现，透视巨头开年业绩走向。默沙东默沙东公布2025年第一季度业绩，总营收155.29亿美元，同比下降2%，其中制药业务收入136.38亿美元，同比下降3%。中国区收入同比下滑62%至6.68亿美元，占据默沙东全球制药业务4.9%的份额。研发投入为36.21亿美元，同比下降9%。 2025年Q1，Keytruda（帕博利珠单抗）依然稳稳地撑起了默沙东的收入大盘，以4%的增长速度创收72.05亿美元，其销售额约占默沙东Q1总营收的46%。K药的增长主要得益于全球对早期适应症（包括三阴性乳腺癌、肾细胞癌和非小细胞肺癌），以及转移适应症（包括膀胱癌、子宫内膜癌和MSI-H癌症）的持续强劲需求。此外，默沙东成功研发出了K药的皮下注射制剂，大幅缩短了给药时间，平均仅需2分钟。目前，该制剂的上市申请正在接受美国和欧洲监管机构的审查，美国的PDUFA日期定于今年9月23日。默沙东其他的肿瘤产品也有不错表现。全球首创HIF-2α抑制剂Welireg取得1.37亿美元的销售额，同比增长62%。合作开发产品Lynparza（奥拉帕利）、Lenvima（仑伐替尼）、Reblozyl（罗特西普）则分别为默沙东带来了3.21、2.58、1.19亿美元的收入。HPV疫苗Gardasil/Gardasil 9在Q1的销售额为13.27亿美元，同比下降41%，这主要下是由于中国地区需求下降，库存仍居高不下。除中国外，其销售额增长14%。不久前，Gardasil 9在华获批新适应证，适用于16-26岁男性接种。心血管领域，肺动脉高压（PAH）新药Winrevair收入2.8亿美元，该药物是第一个被批准用于治疗PAH的激活素信号抑制剂疗法，仅需每3周皮下注射一次。在III期ZENITH研究中，与安慰剂相比，Winrevair将PAH的全因死亡、肺移植和住院综合风险降低了76%，由于中期分析的压倒性疗效，该研究提前停止。默沙东还引进了恒瑞的一款口服Lp(a)抑制剂HRS-5346，以扩展和补充其心血管代谢产品管线，交易首付款为2亿美元，里程碑付款最高可达17.7亿美元。默沙东预计2025年全年销售额将在641亿美元至656亿美元之间，这一展望包括美国政府迄今对其他国家进口商品实施的关税的影响，以及外国政府对美国征收的关税，其中最主要的关税与中国有关。默沙东估计关税将导致约2亿美元的增量成本，对毛利率产生负面影响。罗氏2025年第一季度，罗氏总营收154.40亿瑞士法郎（约172.40亿美元，按2025年平均汇率换算，1瑞士法郎=1.1166美元，下同），同比增长6%（按固定汇率计算），其中制药业务收入119.49亿瑞士法郎（约133.42亿美元，+8%），诊断业务收入34.91亿瑞士法郎（约38.98亿美元，与去年Q1持平）。此外，中国区制药业务实现了强劲增长（+14%）。今年第一季度，罗氏共有3款创新药的销售额超过十亿美元，其中Phesgo（帕妥珠单抗曲妥珠单抗皮下注射制剂）、Vabysmo（法瑞西单抗）、Xolair（玛巴洛沙韦）和Hemlibra（艾美赛珠单抗）表现突出，分别收入5.93亿瑞士法郎（约6.62亿美元，+52%）、10.18亿瑞士法郎（约11.37亿美元，+18%）、6.45亿瑞士法郎（约7.20亿美元，+26%）和11.65亿瑞士法郎（约13.01亿美元，+11%）。管线进展方面，罗氏透露了将在今年启动Aβ双抗Trontinemab治疗阿尔茨海默病的III期研究的计划，并披露了3个被剔除的项目，包括：①TGF-β3 单抗RG6315治疗纤维化的I期研究②Muc1 CAR T细胞疗法P-MUC1C-ALLO1治疗实体瘤的I期研究③TIGIT单抗tiragolumab联合阿替利珠单抗治疗局部晚期食管癌的III期研究。赛诺菲2025年第一季度，赛诺菲总营收98.95亿欧元（约104.57亿美元，按2025年平均汇率换算，1欧元=1.0568美元，下同），同比增长9..7%（按固定汇率计算，下同）；研发投入18.08亿欧元（约19.11亿美元，+6.9%），占总营收的18.3%。从地域分布来看，美国市场收入46.57亿欧元（约49.22亿美元，+15.4%），欧洲市场收入20.43亿欧元（约21.59亿美元，+0.5%），中国市场收入7.01亿欧元（约7.41亿美元，-1.7%），从业务板块来看，赛诺菲免疫、罕见病、神经、肿瘤、疫苗以及其他类六大板块分别收入35.91亿欧元（约37.95亿美元）、15.66亿欧元（约16.55亿美元）、0.65亿欧元（约0.69亿美元）、2.55亿欧元（约2.69亿美元）、13.27亿欧元（约14.02亿美元）和30.92亿欧元（约32.68亿美元）。除了业绩，赛诺菲也在财报中透露了今年将达成的重要里程碑事件：度普利尤单抗治疗天疱疮（BP）的上市申请将在6月20日之前迎来FDA的审批决定第二季度将在美国递交艾沙妥昔单抗皮下制剂的上市申请2025年下半年将启动TL1A单抗Duvakitug的首个III期临床试验 2025年下半年将公布IL-33单抗Itepekimab治疗COPD的 III期研究数据，并在欧美递交其上市申请2025年下半年将公布TNFR1抑制剂balinatunfib治疗类风湿性关节的II期研究数据CD3单抗替利珠单抗用于延缓1型糖尿病发病的上市申请将在2025年下半年迎来中国国家药监局的审批决定2025年下半年将公布RSV mRNA疫苗SP0256的II期研究数据血友病RNAi疗法fitusiran的上市申请将在2025年下半年迎来中国国家药监局的审批决定BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症的上市申请将在8月29日之前迎来FDA的审批决定BTK抑制剂Tolebrutinib治疗非复发性继发进展型多发性硬化症的上市申请将在9月28日之前迎来FDA的审批决定2025年下半年将公布BTK抑制剂Tolebrutinib治疗原发进展型多发性硬化症的III期研究数据2025年下半年将公布核药SAR447873治疗胃肠胰神经内分泌肿瘤的最终II期数据百时美施贵宝2025年第一季度，BMS总收入为112亿美元（-6%），其中美国收入为79亿美元（-7%），其他地区收入为33亿美元（-2%）。 BMS把产品划分为增长产品（Growth Products）和成熟产品（Legacy Products），一季度增长产品收入为56亿美元（+16%），主要由Opdivo、Breyanzi、Reblozyl 、Camzyos和Cobenfy等产品驱动。鉴于这一增长，BMS将2025年收入指引上调至458亿~468亿美元。从BMS肿瘤、血液、心血管、免疫和神经科学五大业务板块的重点产品来看，有以下显著变化：肿瘤产品Opdivo（纳武利尤单抗）和Opdualag（纳武利尤单抗+瑞拉利单抗）分别创收22.65亿美元和6.24亿美元（+9%，+7%），Abraxane（白蛋白紫杉醇）收入大幅下滑（-52%）至1.05亿美元，全球第2款KRAS G12C抑制剂Krazati（阿达格拉西）一季度收入4800万美元（+125%）；心血管领域，全球首创心肌肌球蛋白抑制剂Camzyos（玛伐凯泰）收入大幅增长（+89%），一季度全球收入1.59亿美元。目前，Camzyos已获批适应症为梗阻性肥厚型心肌病，治疗非梗阻性肥厚型心肌病III期研究未达到主要终点。该产品全球患者人数现达1.1万人，FDA近日更新该药物标签，减少维持期和禁忌症患者的超声心动图监测要求，有望继续扩大患者范围；血液学板块，Revlimid（来那度胺）和Pomalyst（泊马度胺）收入均下滑，CD19 CAR-T疗法Breyanzi销售继续大幅增长（+146%），单季度创收2.63亿美元；免疫板块产品Sotyktu收入5500万美元（+27%），该产品于2025年1月起受美国市场准入条件改善影响，拉动销售增长；神经科学领域，Cobenfy仍在市场拓展初期，一季度收入2700万美元。Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

财报临床3期疫苗引进/卖出

2025-04-24

·正大天晴药业集团

12项口头报告创中国药企最高纪录，正大天晴多瘤种创新管线闪耀2025ASCO

当地时间4月23日，美国临床肿瘤学会2025大会重磅揭晓中稿信息。正大天晴多瘤种创新管线再创纪录——12项口头报告（oral presentation），创下中国药企口头报告最高纪录，其中更包括4项最新重磅摘要（Late-breaking Abstract，LBA）。加上壁报和摘要收录等形式，共有40多项创新成果将在大会公布最新临床数据，展现多瘤种创新引领实力。本届 ASCO 年会将于当地时间5月30日-6月3日在美国芝加哥举办，敬请关注。12项口头报告创中国药企纪录安罗替尼、贝莫苏拜单抗、派安普利单抗、TQB2102、LM-108领衔创新产品群亮相本次大会，充分展示公司产品市场潜力。尤为值得关注的是，包括与贝莫苏拜单抗联用在内，安罗替尼此次共有9项研究入选口头报告，为国产创新药之最。LBA口头报告1.CAMPASS研究: 贝莫苏拜单抗联合安罗替尼对比帕博利珠单抗一线治疗晚期非小细胞肺癌：一项随机、单盲、多中心的III期研究#LBA8502：CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.入选形式：LBA 口头报告通讯作者：上海市胸科医院韩宝惠第一作者：上海市胸科医院韩宝惠2.R-ALPS研究：一项贝莫苏拜单抗联合或不联合安罗替尼用于同步/序贯放化疗后未进展的局部晚期、不可切除(III期)非小细胞肺癌的巩固治疗的随机、双盲、平行对照、多中心III期临床研究#LBA8004：R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.入选形式：LBA 口头报告通讯作者：中山大学肿瘤防治中心陈明第一作者：中山大学肿瘤防治中心陈明3.STUPP方案联合或不联合安罗替尼治疗新诊断胶质母细胞瘤的疗效及安全性：一项多中心、随机、双盲的II期临床试验结果 #LBA2000：Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial. 入选形式：LBA 口头报告通讯作者：中山大学肿瘤防治中心陈忠平第一作者：中山大学肿瘤防治中心陈媛媛4.安罗替尼对比贝伐珠单抗联合化疗一线治疗RAS/BRAF野生型不可切除转移性结直肠癌：一项多中心、前瞻性、随机III期临床研究（ANCHOR研究）#LBA3502：Anlotinib versus Bevacizumab Added to Standard First-line chemotherapy Among Patients With RAS/BRAF Wild-type, unresectable Metastatic Colorectal cancer: A multicenter, prospective, Randomised, phase 3 Clinical Trial (ANCHOR trial)入选形式：LBA 口头报告通讯作者：浙江大学医学院附属第二医院丁克峰第一作者：浙江大学医学院附属第二医院丁克峰▲ 上下滑动查看更多口头报告1.安罗替尼联合表柔比星序贯安罗替尼维持治疗对比安慰剂联合表柔比星作为晚期软组织肉瘤（STS）一线治疗的随机、双盲、平行对照Ⅲ期研究#11501：Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.入选形式：口头报告通讯作者：复旦大学附属中山医院周宇红、北京积水潭医院牛晓辉第一作者：复旦大学附属中山医院周宇红2.贝莫苏拜单抗联合卡铂/紫杉醇方案联合或不联合安罗替尼序贯贝莫苏拜单抗联合或不联合安罗替尼维持治疗用于晚期复发子宫内膜癌的一线治疗：一项随机、开放II期临床试验#5508：Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.入选形式：口头报告通讯作者：上海市第十人民医院陈晓军第一作者：上海市第十人民医院陈晓军3.注射用TQB2102，新型双特异性抗HER2抗体偶联药物，在晚期实体瘤患者中的安全性和有效性：首次人体I期临床研究初步数据#3003：Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.入选形式：口头报告通讯作者：中山大学肿瘤防治中心徐瑞华、王树森第一作者：中山大学肿瘤防治中心徐瑞华、王树森4.一项评估catequentinib hydrochloride（AL3818，盐酸安罗替尼胶囊）对比安慰剂治疗转移性或晚期平滑肌肉瘤（LMS）患者的随机 III 期临床研究#11506：A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).入选形式：口头报告通讯作者：英国皇家马斯登国民保健服务基金会信托基金和癌症研究所 Robin Jones第一作者：英国皇家马斯登国民保健服务基金会信托基金和癌症研究所 Robin Jones5.贝莫苏拜单抗联合化疗序贯联合安罗替尼一线治疗局部晚期或转移性鳞状非小细胞肺癌（sq-NSCLC）的III期临床研究#8514：Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC)入选形式：快速口头报告通讯作者：中国医学科学院肿瘤医院石远凯第一作者：中国医学科学院肿瘤医院石远凯6.艾立布林联合安罗替尼治疗晚期软组织肉瘤患者：疗效和生物标志物最新进展#11502：Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers入选形式：口头报告通讯作者：四川大学华西医院姜愚第一作者：四川大学华西医院刘杰▲ 上下滑动查看更多Clinical Science Symposium1.派安普利单抗联合化疗新辅助治疗HPV阴性局部晚期头颈部鳞状细胞癌：一项II期临床试验#6011：REMATCH2201: A phase II study on reducing surcical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhilbitor and AP chemotherapy入选形式：Clinical Science Symposium通讯作者：华中科技大学同济医学院附属协和医院杨坤禹第一作者：华中科技大学同济医学院附属协和医院杨坤禹2.抗CCR8单克隆抗体cafelkibart（LM-108）联合抗PD-1疗法治疗胰腺癌的有效性与安全性：1/2期研究结果#4010：Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: results from phase 1/2 studies.入选形式：Clinical Science Symposium通讯作者：北京大学肿瘤医院沈琳第一作者：北京大学肿瘤医院龚继芳▲ 上下滑动查看更多多瘤种前沿创新全面开花除口头报告外，还有30多项研究覆盖肺癌、骨与软组织肉瘤、消化系统肿瘤、乳腺癌等多个瘤种，展现了正大天晴的多瘤种创新实力。（不包含口头报告）肺癌1.安罗替尼联合第三代EGFR-TKIs治疗EGFR-TKIs治疗后缓慢进展或寡进展的晚期非小细胞肺癌的回顾性研究（ALTER-L058）#8600：A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058)入选形式：壁报通讯作者：同济大学附属上海市东方医院周彩存第一作者：同济大学附属上海市东方医院周彩存2.安罗替尼联合放疗在无法耐受同步放化疗的局部晚期非小细胞肺癌患者中的安全性与有效性：一项II期临床试验的初步结果#8043：Safety and efficacy of radiotherapy combined with anlotinib in locally advanced non-small cell lung cancer patients intolerant to concurrent chemoradiotherapy: Preliminary result of a phase II clinical trial.入选形式：壁报通讯作者：中国医学科学院肿瘤医院王健仰第一作者：中国医学科学院肿瘤医院苑雨培3.大分割放疗序贯替雷利珠单抗及安罗替尼新辅助治疗II-IIIA期非小细胞肺癌的前瞻性II期研究的初步结果#8063：Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).入选形式：壁报通讯作者：浙江省肿瘤医院曾剑、季永领第一作者：浙江省肿瘤医院方敏▲ 上下滑动查看更多骨与软组织肉瘤安罗替尼联合吉西他滨和多西他赛治疗复发或转移性骨原发恶性肿瘤的初步结果：一项开放标签、单臂、多中心临床研究 #e23507：Preliminary results of anlotinib combined with gemcitabine and docetaxel forrecurrent or metastatic primary malignant bone tumors: an open-label, single-arm,multicenter clinical trial.入选形式：摘要收录通讯作者：中山大学附属第一医院沈靖南第一作者：中山大学附属第一医院卞艺颖消化系统肿瘤1.ALTER-E009研究更新结果：安罗替尼联合放疗治疗局部晚期或转移性食管鳞癌的有效性与安全性：一项多中心、多队列、回顾性探索研究 #e16110：Updated Results of the ALTER-E009 Study: Efficacy and Safety of Anlotinib Combined with Radiotherapy in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): A Multicenter, Multi-cohort Retrospective Exploratory Study入选形式：摘要收录通讯作者：山东省肿瘤医院李宝生第一作者：中国医学科学院肿瘤医院王鑫2.FAITH试验：安罗替尼联合贝莫苏拜单抗用于既往接受过免疫治疗的中晚期肝细胞癌患者的可行性与安全性：一项单臂、多中心、前瞻性II期研究 #e16225：FAITH trial: feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma: a multicenter, single arm, prospective phase Ⅱ trial入选形式：摘要收录通讯作者：复旦大学附属中山医院孙惠川第一作者：复旦大学附属中山医院沈英皓3.ALTER-PA001：安罗替尼和贝莫苏拜单抗联合AG方案对比AG方案一线治疗转移性胰腺癌的多中心探索性临床研究#TPS4228：ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer入选形式：壁报通讯作者：上海交通大学医学院附属仁济医院王理伟第一作者：上海交通大学医学院附属仁济医院崔玖洁4.TQB2103，一种靶向Claudin18.2的抗体偶联药物，在晚期恶性实体瘤受试者中的首次人体 I 期临床研究#3026：First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors入选形式：壁报通讯作者：浙江省肿瘤医院程向东第一作者：浙江省肿瘤医院程向东5.TQB2868联合安罗替尼和白蛋白结合型紫杉醇/吉西他滨一线治疗转移性胰腺癌的单臂、开放II期临床研究#4159：TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study入选形式：壁报通讯作者：复旦大学附属肿瘤医院虞先濬，河南省肿瘤医院陈小兵第一作者：复旦大学附属肿瘤医院施思6.安罗替尼与派安普利单抗联合GEMOX一线治疗晚期胆道癌的初步结果：一项单中心单臂探索性研究#e16195：Preliminary results of anlotinib and penpulimab (anti-PD1) combined with GEMOX in first-line treatment of advanced biliary tract cancer: A single-center, single-arm exploratory study.入选形式：摘要收录通讯作者：北京协和医院管梅第一作者：北京协和医院张智旸7.安罗替尼联合替雷利珠单抗和化疗二线治疗胰腺导管腺癌：一项探索性研究初步结果#e16394：Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A phase II clinical trial.入选形式：摘要收录通讯作者：西安交通大学第一附属医院吴胤瑛第一作者：西安交通大学第一附属医院董旭媛8.安罗替尼联合贝莫苏拜单抗联合白蛋白结合型紫杉醇及顺铂一线治疗晚期胆道系统肿瘤的探索性研究#e16224：Updated results of anlotinib plus benmelstobart combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.入选形式：摘要收录通讯作者：郑州大学第一附属医院宗红第一作者：郑州大学第一附属医院靳水玲9.恩沃利单抗联合安罗替尼及替吉奥治疗二线及以上晚期胰腺癌的疗效及安全性观察#e16385：Efficacy and safety of second-line therapy by envafolimab combined with anlotinib and S-1 in pancreatic cancer patients: A single-arm, phase II clinical trial.入选形式：摘要收录通讯作者：安徽医科大学第一附属医院张梅第一作者：安徽医科大学第一附属医院朱治法▲ 上下滑动查看更多乳腺癌1.后CDK4/6抑制剂时代的新选择：以安罗替尼为基础的联合方案治疗CDK4/6抑制剂耐药的HR阳性转移性乳腺癌的多中心真实世界研究#e13059：A New Option for post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6 Inhibitors入选形式：摘要收录通讯作者：湖南省肿瘤医院欧阳取长第一作者：湖南省肿瘤医院刘斌亮2.ETER901研究：一项评估安罗替尼联合抗 PD-L1 抗体贝莫苏拜单抗（TQB2450）对比白蛋白结合型紫杉醇作为复发或转移性三阴性乳腺癌患者一线治疗的疗效与安全性随机、开放III期临床研究#1104：ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.入选形式：壁报通讯作者：中国医学科学院附属肿瘤医院徐兵河第一作者：中国医学科学院附属肿瘤医院王佳玉3.TQB2102新辅助治疗在局部晚期或早期HER2阳性乳腺癌女性患者中的有效性和安全性：一项随机、开放标签、II期临床试验#591：Efficacy and safety of neoadjuvant TQB2102 in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial入选形式：壁报通讯作者：复旦大学附属肿瘤医院邵志敏第一作者：复旦大学附属肿瘤医院李俊杰4.TQB2102在HER2低表达复发或转移性乳腺癌患者中的初步疗效与安全性：一项1b期临床研究结果#1090：Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study.入选形式：壁报通讯作者：中山大学肿瘤防治中心王树森，哈尔滨医科大学附属肿瘤医院张清媛第一作者：中山大学肿瘤防治中心王树森5.TQB2930，HER2双特异性抗抗体，联合化疗在既往接受过≥2线治疗的Her2阳性乳腺癌中的疗效和安全性：一项Ib/II期研究结果#1033： Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.入选形式：壁报通讯作者：哈尔滨医科大学附属肿瘤医院张清媛第一作者：哈尔滨医科大学附属肿瘤医院张清媛6.派安普利单抗联合TP方案新辅助治疗TNBC的单臂、开放、多中心II期临床研究(neoTAPPL)#588： Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: A single-arm, open-label, multi-center phase II clinical study (neoTAPPL).入选形式：壁报通讯作者：陆军军医大学第一附属医院齐晓伟第一作者：陆军军医大学第一附属医院阎文婷7.替雷利珠单抗联合安罗替尼和AT方案新辅助治疗TNBC的初步疗效和安全性#e12600：The preliminary efficacy and safety results of neoadjuvant phase II study of anlotinib plus tislelizumab combined with chemotherapy in triple-negative breast cancer.入选形式：摘要收录通讯作者：四川省人民医院罗静第一作者：四川省人民医院罗静▲ 上下滑动查看更多妇科肿瘤ALTER-GO-020试验结果：安罗替尼联合派安普利单抗一线治疗持续性、复发性或转移性宫颈癌的II期研究 #5527：A phase II study of Anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.入选形式：壁报通讯作者：四川省肿瘤医院张国楠第一作者：四川省肿瘤医院王登凤头颈部肿瘤1.安罗替尼新辅助治疗局部晚期分化型甲状腺癌（DTC）的有效性与安全性：一项多中心、单臂、II期研究 #6096：Efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced differentiated thyroid cancer (DTC): A multicenter, single-arm, phase II study入选形式：壁报通讯作者：天津市人民医院高明第一作者：天津市肿瘤医院李大鹏2.派安普利单抗联合化疗新辅助治疗局部晚期可切除头颈部鳞状细胞癌患者的II期临床研究 #e18098：A phase II clinical study of neoadjuvant penpulimab combined with chemotherapy for patients with locoregionally advanced, resectable squamous cell carcinoma of the head and neck入选形式：摘要收录通讯作者：上海交通大学附属第九人民医院张陈平、阮敏第一作者：上海交通大学附属第九人民医院韩楠男3.Tim-3抑制剂TQB2618联合派安普利单抗和化疗一线治疗复发/转移性鼻咽癌：一项单臂，双队列，2期研究#6031：Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a single-arm, two-cohort, phase 2 study入选形式：壁报通讯作者：中山大学肿瘤防治中心马骏、蔡清清第一作者：中山大学肿瘤防治中心徐骋4.安罗替尼联合碘131治疗远处转移分化型甲状腺癌的疗效与安全性临床研究#e18133：Efficacy and safety of anlotinib combined with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: A single-arm, phase II clinical study.入选形式：摘要收录通讯作者：天津市肿瘤医院空港医院戴东第一作者：天津市肿瘤医院空港医院戴东▲ 上下滑动查看更多泌尿系统肿瘤1.贝莫苏拜单抗联合安罗替尼对比舒尼替尼一线治疗晚期肾细胞癌的III期临床研究（ETER100）的亚组分析 #4536：First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma: Subgroup analysis from the phase 3 ETER100 trial入选形式：壁报通讯作者：北京大学肿瘤医院郭军、中国医学科学院肿瘤医院周爱萍第一作者：北京大学肿瘤医院盛锡楠2.安罗替尼联合依维莫司一线治疗晚期非透明细胞肾细胞癌的1年更新结果：一项单中心、单臂II期临床研究（ALTER-UC-001）#4525：Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma：1 year updated results from UC-001, a single-center, single-arm, phase II trial入选形式：壁报通讯作者：复旦大学附属肿瘤医院张海梁、叶定伟第一作者：复旦大学附属肿瘤医院徐文浩3.安罗替尼联合信迪利单抗治疗非透明细胞肾细胞癌：探索性、前瞻性多中心临床研究初步结果 #4526：Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma(nccRR): Preliminary results from an exploratory prospective multicentre clinical study入选形式：壁报通讯作者：中山大学肿瘤防治中心周芳坚第一作者：中山大学肿瘤防治中心董培▲ 上下滑动查看更多其他瘤种TQ-B3234在成人1型神经纤维瘤病（NF1）患者中的安全性、耐受性及有效性评估：一项开放的1期剂量递增与剂量扩展研究#3108：An open-label phase 1 dose-escalation and dose-expansion trial to evaluate the safety, tolerability, and efficacy of TQ-B3234 in adults with neurofibromatosis type 1(NF1)入选形式：壁报通讯作者：上海交通大学医学院附属第九人民医院李青峰第一作者：上海交通大学医学院附属第九人民医院刘珺中性粒细胞减少预防1.Guard-01：艾贝格司亭α作为同步放化疗诱导中性粒细胞减少一级预防的前瞻性研究#e24100：Guard-01: A prospective study of efbemalenograstim alfa as primary prophylaxis for concurrent chemo-radiotherapy induced neutropenia入选形式：摘要收录通讯作者：中山大学肿瘤防治中心陈明第一作者：中山大学肿瘤防治中心陈媛媛2.Guard-02：艾贝格司亭α在乳腺癌患者化疗当天预防性应用的安全性与有效性#e24088：Guard 02: Safety and efficacy of prophylactic use of novel long-acting G-CSF efbemalenograstim α on same-day of chemotherapy in Breast Cancer Patients入选形式：摘要收录通讯作者：安徽省肿瘤医院潘跃银第一作者：安徽省肿瘤医院周守兵3.Guard-03：艾贝格司亭α在发热性中性粒细胞减少（FN）中风险化疗方案伴危险因素的非小细胞肺癌患者中一/二级预防的随机、多中心、探索性临床研究#e20560：Efbemalenograstim Alfa for the Primary/Secondary Prophylaxis of Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen with Risk Factors in Patients with non-small cell lung cancer (NSCLC)：A Randomized, Multicenter, Exploratory Clinical Trial入选形式：摘要收录通讯作者：天津市肿瘤医院黄鼎智第一作者：天津市肿瘤医院李梦洁4.Guard-05：艾贝格司亭α用于卵巢癌和宫颈癌患者化疗诱导中性粒细胞减少的一级预防：一项单臂、多中心临床试验#e17556：Efbemalenograstim Alfa for Primary Prophylaxis of Chemotherapy-Induced Neutropenia In Patients With Ovarian and Cervical Cancer: A Single-Arm, Multicenter Clinical Trial入选形式：摘要收录通讯作者：山东大学齐鲁医院孔北华第一作者：山东大学齐鲁医院王丽梅▲ 上下滑动查看更多ASCO年会是全球规模最大、学术水平最高、最具权威性的临床肿瘤学会议之一。我们会持续跟进报道正大天晴在本次大会的最新资讯与核心数据，期待这些创新成果早日为肿瘤患者带来更多的生存希望和更好的治疗选择。声明：1. 本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。2. 本公司不对任何药品和/或适应症作推荐。3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。● 从“引领创新”到“投资创新” 中生引领（上海）私募投资基金揭牌成立● 应邀出席中国医学发展大会谢承润：用AI助力患者全周期健康管理，打造亚太多中心临床联盟● 中国工程院党组成员、副院长王辰院士一行到正大天晴调研 ● 双适应症申报获受理！贝莫苏拜方案“头对头”优于替雷联合化疗、覆盖Ⅲ期肺癌巩固治疗

ASCO会议临床结果临床2期临床3期

2025-04-24

·PRNewswire

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB, April 24, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options. "Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. "In multiple studies, pelareorep has repeatedly demonstrated its ability to engage the immune system to attack pancreatic cancer tumors, which has the potential to improve outcomes for patients battling this difficult-to-treat cancer." Abstract Number: 2562 Title: Role of pelareorep in activating anti-tumor immunity in PDAC. Presentation Type: Poster Session Title: Developmental Therapeutics – Immunotherapy Session Date and Time: June 2, 2025, 1:30 - 4:30 p.m. CT Abstracts will be published on the ASCO website at 5:00 p.m. ET on May 22, 2025. About GOBLET The GOBLET ( Gastrointestinal tum Ors exploring the treatment com Binations with the oncolytic reovirus pe Lar Eorep and an Ti-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH. The primary endpoints of the study are objective response rate (ORR) and/or disease control rate assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study comprises five treatment groups: Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line advanced/metastatic pancreatic cancer patients; Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients; Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients; and Pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients. Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients. About AIO AIO-Studien-gGmbH (AIO) emerged from the study center of the medical oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our belief that there are multiple clinical and regulatory options for bringing pelareorep to patients; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics Michael Rubenstein LifeSci Communications [email protected] Logo - SOURCE Oncolytics Biotech® Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果免疫疗法ASCO会议快速通道临床2期

100 项与白蛋白结合型紫杉醇相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性胰腺腺癌	美国	Teva Pharmaceuticals, Inc.	2023-05-11
胰腺腺癌	美国	Bristol Myers Squibb Co.	2013-09-06
非小细胞肺癌	日本	Taiho Pharmaceutical Co., Ltd.	2010-07-23
胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	2010-07-23
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	2010-07-23
乳腺癌	中国	Abraxis BioScience, Inc.	2008-06-30
转移性乳腺癌	美国	Bristol Myers Squibb Co.	2005-01-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期乳腺癌	临床3期	中国	石药集团欧意药业有限公司	2023-04-27
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	智利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	捷克	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	法国	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	意大利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	波兰	Hoffmann-La Roche, Inc.	2019-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04581343 (PanCAN-SR1, CTgov)	临床1期	转移性胰腺癌 \| 转移性胰腺导管腺癌	10	Canakinumab	鑰繭窪構壓獵觸積簾膚 = 遞糧遞壓鹹鏇廠鏇構壓鹽製遞顧獵廠遞齋餘鏇 (選襯選構淵顧顧鹽醖構, 淵鑰艱憲艱淵憲選遞鹹 ~ 鏇願廠築襯膚遞繭夢製) 更多	-	2025-04-08
Pubmed \| Int J Cancer 人工标引	临床2期	局部晚期食管鳞状细胞癌新辅助	46	tislelizumab + nab-paclitaxel + cisplatin	襯願積願顧構齋網壓淵(壓顧壓鬱艱膚膚淵鹽網) = 淵憲範獵膚繭獵顧繭製醖範糧鹹糧襯顧鏇顧鏇 (願顧壓築簾壓網艱觸壓 ) 更多	积极	2025-04-01
				tislelizumab + paclitaxel + cisplatin	襯願積願顧構齋網壓淵(壓顧壓鬱艱膚膚淵鹽網) = 製襯衊襯鑰製餘齋壓窪醖範糧鹹糧襯顧鏇顧鏇 (願顧壓築簾壓網艱觸壓 ) 更多
NCT03240016 (ABLE, CTgov)	临床2期	晚期尿路上皮癌 \| 膀胱尿路上皮癌	36	Abraxane+pembrolizumab	鬱範築鏇衊糧積廠糧製 = 艱憲齋鬱窪遞繭獵膚醖積簾憲艱壓齋鏇壓遞構 (醖齋膚蓋製觸選簾獵構, 鑰憲廠窪衊鏇壓鹹衊蓋 ~ 簾製襯鹽淵構蓋觸襯餘) 更多	-	2025-01-16
NCT05244993 (NEWS) 人工标引	临床2期	晚期三阴性乳腺癌一线	43	安罗替尼 +派安普利单抗 +白蛋白紫杉醇	憲蓋淵鏇簾淵鏇淵鬱膚(鑰糧淵鑰繭鏇鹹窪築糧) = 積醖鹽鹹獵網鹹衊遞鹽憲壓製顧糧積醖窪餘衊 (窪願願選構廠蓋壓淵範 ) 更多	积极	2024-12-14
NCT05659056 (SABCS2024) 人工标引	临床2期	HER2阳性乳腺癌新辅助 HER2 Positive	52	pyrotinib + trastuzumab + nab-paclitaxel	餘鏇窪繭淵壓構製蓋遞(簾鑰積製築窪選糧衊壓) = 鹹齋鹽膚鬱鬱選膚鏇繭廠糧鏇遞壓遞衊齋顧鹽 (鹹廠鏇膚網鬱膚餘醖鹽, 29.0 ~ 56.7) 更多	积极	2024-12-10
				pyrotinib + trastuzumab + nab-paclitaxel (HER2-enriched subtype)	餘鏇窪繭淵壓構製蓋遞(簾鑰積製築窪選糧衊壓) = 蓋鏇選鹽糧網壓願夢醖廠糧鏇遞壓遞衊齋顧鹽 (鹹廠鏇膚網鬱膚餘醖鹽, 37.9 ~ 73.2)
NEWS 人工标引	临床3期	乳腺癌	-	SYHX2011	鏇顧夢淵襯廠鹹鏇繭膚(遞憲鹹鏇願觸醖獵艱鏇): HR = 1.38 (95% CI, 1.040 ~ 1.842) 更多	积极	2024-12-10
				紫杉醇（白蛋白结合型）
NCT02754726 (CTgov)	临床2期	转移性胰腺导管腺癌	35	nivolumab+albumin-bound paclitaxel+Gemcitabine+Paricalcitol+cisplatin	艱鑰積艱憲選壓醖簾觸 = 積願觸餘糧遞願衊獵築衊蓋願膚鬱積獵範餘壓 (壓衊襯構鹹淵網鏇繭鏇, 憲網鏇繭鬱憲觸鬱憲製 ~ 遞積鹽製築餘鏇膚顧築) 更多	-	2024-12-10
ESMO_ASIA2024	N/A	乳腺癌新辅助 neutrophil-to-lymphocyte ratio (NLR)	142	nab-paclitaxel (Low NLR (<2.1))	積鏇窪憲廠製夢築鹹觸(鏇醖憲醖淵鹽觸鹽餘網) = DFS in the low NLR group was longer than in the high NLR group 襯廠壓壓遞積淵餘膚獵 (衊獵製獵鏇築範窪網蓋 )	-	2024-12-07
				nab-paclitaxel (High NLR (≥2.1))
NCT03768414 (SWOG S1815 \| SWOG 1815, CTgov)	临床3期	不可切除的肝内胆管癌 \| 晚期胆道癌 \| 胆囊肿瘤 ... 更多	452	Nab-paclitaxel+Gem+Cisplatin (Gem+Cisplatin+Nab-paclitaxel)	膚襯鹽窪選膚糧遞鑰夢(蓋構艱鏇餘齋襯範廠鬱) = 膚窪網繭鏇鑰網鹽餘醖網鑰築鹽製衊廠積顧齋 (願範襯願壓醖餘糧願鑰, 鹹廠壓製憲醖糧獵遞積 ~ 範淵窪淵窪醖獵糧築鹽) 更多	-	2024-10-22
				Gemcitabine+Cisplatin (Gemcitabine + Cisplatin)	膚襯鹽窪選膚糧遞鑰夢(蓋構艱鏇餘齋襯範廠鬱) = 製醖積鬱鹹衊築蓋獵鑰網鑰築鹽製衊廠積顧齋 (願範襯願壓醖餘糧願鑰, 壓壓淵蓋夢簾範繭襯遞 ~ 繭廠膚衊夢獵膚鹹選鹽) 更多
NCT04964960 (CTgov)	临床2期	代谢综合征 \| 非小细胞肺癌 \| 脑转移瘤	3	nab paclitaxel+Carboplatin+Paclitaxel+Pembrolizumab+Pemetrexed	簾觸獵齋鹽遞淵顧網鬱 = 衊衊窪願願鑰範夢鏇網觸淵構蓋淵遞簾鹽憲選 (遞鹽鬱壓壓願選廠膚繭, 蓋窪網膚鏇鹽遞窪鬱憲 ~ 選製觸觸膚遞遞糧網願) 更多	-	2024-10-21